A newly developed proteomic risk score outperforms traditional kidney failure risk tools in predicting ESKD among APOL1 high-risk carriers. A newly developed plasma proteomic risk score accurately ...
The nomination still has to be confirmed by the U.S. Senate. (HealthDay News) — After months of leadership changes, President Donald Trump has chosen a new candidate to lead the U.S. Centers for ...
Health Secretary Robert F. Kennedy Jr. said access could reduce black market use. (HealthDay News) — The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be ...
Nearly half of responses from five popular chatbots were problematic, particularly about stem cells, athletic performance, and nutrition. (HealthDay News) — Chatbots perform poorly when answering ...
Difference largest in acute low back pain case, but lower scores were seen across five standardized care cases ...
Disproportionate increases seen across Black and Hispanic individuals, particularly in opioid-stimulant and opioid-only profiles.
No increase seen in incidence of major bleeding, adverse events, or serious adverse events compared with placebo.
MRI-guided transurethral ultrasound ablation associated with less blood loss, shorter stays, and less pain than robotic prostatectomy.
Alkylating and platinating agent exposure in childhood cancer survivors is associated with impaired spermatogenesis and azoospermia.
A trial compared patient-reported outcome measures after percutaneous nephrostomy vs JJ ureteric stent for urinary tract decompression in patients with obstructive stones.
FDA grants Priority Review to enfortumab vedotin plus pembrolizumab for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS risk.
For those diagnosed by age 16 years, younger age at diagnosis linked to higher GPA, lower probability of school dropout.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results